Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D21SVO
|
|||
| Drug Name |
GSK3858279
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Osteoarthritis pain [ICD-11: MG30.31] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C motif chemokine 17 (CCL17) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05838755) A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17. U.S.National Institutes of Health. | |||
| REF 2 | Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019 Jun;15(6):355-363. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.